(Reuters) – Prospects for AstraZeneca’s respiratory treatments business improved on Wednesday as a three-drug inhaler was shown to ease smoker’s lung and U.S. regulators granted its injectable asthma drug Fasenra special status for a rare lung condition.
AstraZeneca said the late-stage ETHOS trial of triple-drug therapy Breztri Aerosphere, formerly known as PT010, helped patients suffering from chronic obstructive pulmonary disease (COPD), in a challenge to Glaxosmithkline’s Trelegy Ellipta.
Colloquially known as smoker’s lung, COPD is a progressively worsening and potentially deadly condition that affects more than 380 million people worldwide, primarily caused by smoking but also by occupational hazards such as air pollution or chemical fumes.
Breztri was shown to lower the risk of a recurrence in flare-ups, or exacerbations, when compared to standard two-drug inhalers, adding to previous evidence here! that the drug helped those without prior exacerbations.